Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

How often H. pylori comes back and what affects its return.

Official title: Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.

Run by Sohag University · NCT07045857 · Data updated 2026-11-12

This project will follow adults aged 18–75 who were treated for H. pylori to see how often the infection returns and which eradication regimens lower that risk.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment100 (estimated)
SponsorSohag University
Academic / other
Locations1 site (Sohag)
StatusRecruiting
StartedMay 13, 2025
Main results expectedNovember 20, 2025
Study endsNovember 20, 2025
Registry record updatedJuly 1, 2025
Trial IDNCT07045857 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–75 with a confirmed H. pylori infection who have received standard eradication therapy, have symptoms such as dyspepsia or peptic ulcer disease, and have normal liver, kidney, and blood test results.

Probably not a fit

Patients with recent use of proton pump inhibitors, H2 blockers, bismuth, or antibiotics within four weeks, active malignancy, severe unstable comorbidities, or recent significant gastrointestinal bleeding are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study follows adults with confirmed H. pylori infection who completed medical eradication therapy and tracks them over time for recurrence. Participants will undergo periodic testing (urea breath test, stool antigen, or endoscopy/biopsy when indicated) and clinical assessments to document any return of infection. Investigators will collect data on the eradication regimen used, medication adherence, demographics, and comorbidities to identify factors associated with recurrence. The primary outcomes are recurrence rate and differences in recurrence between treatment approaches.

Why it matters

Potential benefit: If successful, the results could help doctors choose treatments and follow-up plans that reduce H. pylori coming back for future patients.

How similar studies have gone: Many prior studies have measured H. pylori recurrence and compared eradication regimens, so this approach is consistent with existing research though local results may vary.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 18-75 years old.
* H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).
* Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.
* Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.

Exclusion Criteria:

* Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.
* Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).
* Malignancies: Active or recent malignancies.
* Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).

Where it's running

  • Sohag University Hospital
    Sohag, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.